1-3 of 3
Ute Rehwald
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Brief Report
Holger Schulz, Ute Rehwald, Franck Morschhauser, Thomas Elter, Christoph Driessen, Thomas Rüdiger, Peter Borchmann, Roland Schnell, Volker Diehl, Andreas Engert, Marcel Reiser
Journal: Blood
Blood (2008) 111 (1): 109–111.
https://doi.org/10.1182/blood-2007-03-078725
Published: 2008
Includes: Supplemental data
Journal Articles

Treatment of relapsed CD20 + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

Clinical Trials & Observations
Ute Rehwald, Holger Schulz, Marcel Reiser, Markus Sieber, Jan Oliver Staak, Franck Morschhauser, Christoph Driessen, Thomas Rüdiger, Konrad Müller-Hermelink, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2003) 101 (2): 420–424.
https://doi.org/10.1182/blood.V101.2.420
Published: 2003
Journal Articles

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Holger Schulz, Saskia Karina Klein, Ute Rehwald, Marcel Reiser, Axel Hinke, Wolfgang-Ulrich Knauf, Walter-Erich Aulitzky, Manfred Hensel, Michael Herold, Dieter Huhn, Michael Hallek, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2002) 100 (9): 3115–3120.
https://doi.org/10.1182/blood-2002-03-0972
Published: 2002